Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €5.31 EUR
Change Today +0.03 / 0.57%
Volume 56.0
ALNOV On Other Exchanges
EN Paris
As of 9:03 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

novacyt (ALNOV) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/4/15 - €7.64
52 Week Low
09/5/14 - €4.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NOVACYT (ALNOV)

Related News

No related news articles were found.

novacyt (ALNOV) Related Businessweek News

No Related Businessweek News Found

novacyt (ALNOV) Details

Novacyt Société Anonyme develops and sells diagnostic products and services for cancer and infectious diseases. The company offers consumables, which include Gyn vial that holds smear samples and is primarily used for cervical cancer smears; Non-Gyn vial that collects samples and optimizes the quantity of cells collected for use in organ punctures; Novastic, a liquid solution that optimizes the adherence of cells onto the glass slide; and sedimentation systems. It also provides automated analysis instruments, including NovaPrep processor system to perform gynecologic and non-gynecologic preparations from the same fixation medium. The company offers its products through a network of distributors in France and internationally. Novacyt Société Anonyme was founded in 2006 and is based in Vélizy-Villacoublay, France.

Founded in 2006

novacyt (ALNOV) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

novacyt (ALNOV) Key Developments

Novacyt Announces Audited Pro-Forma and Consolidated Earnings Results for the Year Ended December 31, 2014

Novacyt announced audited pro-forma and consolidated earnings results for the year ended December 31, 2014. For the period, on pro-forma basis, the company reported revenue of EUR 7.786 million, EBITDA (pre-excep) loss of EUR 1.290 million, operating loss of EUR 2.325 million and net loss of EUR 4.870 million. For the period, on consolidated basis, the company’s net loss swelled to EUR 3.7 million from EUR 993,000 a year earlier due to higher investment in infrastructure, amortisation and one-off charges. Consolidated sales totalled EUR 4.5 million compared with EUR 1.2 million in 2013. The company booked a loss before interest, tax, depreciation and amortisation of EUR 1.7 million against a loss of EUR 1.2 million, and an operating loss of 1.9 million against an operating loss of EUR 1.3 million. Net operating cash outflow was EUR 0.9 million against EUR 1.1 million a year ago.

Novacyt Société Anonyme Presents at CF&B European Small Cap Event, Apr-27-2015

Novacyt Société Anonyme Presents at CF&B European Small Cap Event, Apr-27-2015 . Venue: Paris, France.

Novacyt Appoints Manuela Gazzard as Commercial Director

Novacyt has appointed Manuela Gazzard as Commercial Director. Manuela joins Novacyt to lead and expand its commercial operations, with a focus on building the global cytology market through NOVAPrep®, Novacyt’s cytology platform. She will be a member of the Novacyt executive management and be responsible for the commercial development of Novacyt’s oncology and infectious disease diagnostic products. At Johnson Matthey/MacfarlanSmith, Manuela has been a Member of the Managing Board of Directors, responsible for Group global commercial strategy development, and all sales, marketing and business development activities. Prior to this, she held senior commercial roles with Johnson and Johnson/Janssen, Boehringer Ingelheim and Zentaris.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALNOV:FP €5.31 EUR +0.03

ALNOV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALNOV.
View Industry Companies

Industry Analysis


Industry Average

Valuation ALNOV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.5x
Price/Book 0.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 29.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVACYT, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at